Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Urol ; 192(5): 1542-8, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24769028

ABSTRACT

PURPOSE: Recurrent prostate cancer remains a major problem. Staging, grading and prostate specific antigen level at surgery are helpful but still imperfect predictors of recurrence. For this reason there is an imperative need for additional biomarkers that add to the prediction of currently used prognostic factors. MATERIALS AND METHODS: We evaluated the extent of promoter methylation of genes previously reported as aberrantly methylated in prostate cancer (AIM1, APC, CCND2, GPX3, GSTP1, MCAM, RARß2, SSBP2 and TIMP3) by quantitative fluorogenic methylation-specific polymerase chain reaction. We used cancer tissue from a nested case-control study of 452 patients surgically treated for prostate cancer. Recurrence cases and controls were compared and the association between methylation extent and recurrence risk was estimated by logistic regression adjusting for patient age at prostatectomy, prostatectomy year, stage, grade, surgical margins and preprostatectomy prostate specific antigen. All statistical tests were 2-sided with p ≤0.05 considered statistically significant. RESULTS: The extent of GSTP1 methylation was higher in patients with recurrence than in controls (p = 0.01), especially patients with early disease, ie organ confined or limited extraprostatic extension (p = 0.001). After multivariate adjustment GSTP1 promoter methylation at or above the median was associated with an increased risk of recurrence, including in men with early disease (each p = 0.05). CONCLUSIONS: Greater GSTP1 promoter methylation in cancer tissue was independently associated with the risk of recurrence in patients with early prostate cancer. This suggests that GSTP1 promoter methylation may be a potential tissue based recurrence marker.


Subject(s)
DNA Methylation , DNA, Neoplasm/genetics , Glutathione S-Transferase pi/genetics , Promoter Regions, Genetic , Prostatic Neoplasms/genetics , Follow-Up Studies , Glutathione S-Transferase pi/metabolism , Humans , Incidence , Male , Maryland/epidemiology , Middle Aged , Neoplasm Recurrence, Local/epidemiology , Neoplasm Recurrence, Local/genetics , Neoplasm Recurrence, Local/metabolism , Prognosis , Prostatectomy , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/surgery , Retrospective Studies
2.
J Virol Methods ; 189(1): 167-71, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23370404

ABSTRACT

The current method of transporting self-collected cervicovaginal specimen for HPV DNA testing relies on liquid based medium, which is challenging and expensive to transport. A novel, dry storage and transportation device, Whatman indicating FTA™ Elute Cartridge, avoids some of the pitfalls of liquid-based medium. This method has been shown to be comparable to liquid-based collection medium, but relative performance of self-collected (SC) and clinician-collected (CC) samples onto FTA cards has not been reported. The objective of this study is to compare the analytic performance of self- and clinician-collected samples onto FTA cartridges for the detection of carcinogenic HPV using Linear Array. There was a 91% agreement, 69% positive agreement, and kappa of 0.75 between the clinician-collected and self-collected specimens for detection of any carcinogenic HPV genotype. When the HPV results were categorized hierarchically according to cervical cancer risk, there was no difference in the distribution of the HPV results for the clinician- and self-collected specimens (p=0.7). This study concludes that FTA elute cartridge is a promising method of specimen transport for cervical cancer screening programs considering using self-collected specimen and HPV testing. Larger studies with clinical endpoints are now needed to assess the clinical performance.


Subject(s)
Papillomavirus Infections/diagnosis , Specimen Handling/methods , Uterine Cervical Neoplasms/diagnosis , Vaginal Smears/methods , Adult , Cervix Uteri/virology , DNA, Viral/genetics , Early Detection of Cancer , Female , Genotype , Humans , Middle Aged , Papillomaviridae/genetics , Uterine Cervical Neoplasms/virology
3.
J Immunol Methods ; 382(1-2): 211-5, 2012 Aug 31.
Article in English | MEDLINE | ID: mdl-22677266

ABSTRACT

Ophthalmic sponges are used to collect undiluted cervical secretions for assessment of markers of genital tract immunity. Heterogeneity in absorbed and extracted sample volumes requires normalization in order to make valid inter-individual comparisons. We evaluated the performance of adjustment by weight and total protein on normalizing inter-individual variability of immune marker measurement due to differences in volume collection. Normalization to total protein resulted in a minimal loss of usable specimens and a significant reduction in the correlation of immune marker concentration to specimen weight compared to weight adjustment. Total protein normalization appeared to be more effective than weight adjustment in reducing the dependence of cervical immune marker concentrations on differences in specimen volume.


Subject(s)
Biomarkers/analysis , Cervix Uteri/immunology , Cervix Uteri/metabolism , Cytokines/analysis , Data Interpretation, Statistical , Cohort Studies , Cytokines/immunology , Female , Humans , Menopause/immunology , Prospective Studies
4.
Cytokine ; 56(3): 798-803, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22015106

ABSTRACT

INTRODUCTION: Women≥45years of age with persistent HPV infections have distinct peripheral circulating immune profiles. Few studies have comprehensively evaluated the cervical immunologic microenvironment in HPV-positive and HPV-negative perimenopausal women. METHODS: We collected cervical secretion specimens from 34 high risk HPV (HR-HPV) positive and 44 HR-HPV negative women enrolled in an ongoing prospective cohort assessing the natural history of HPV across the menopausal transition. We used these specimens to quantify concentrations of 27 different immune markers using multiplexed bead-based immunoassays. RESULTS: HR-HPV positive women had significantly higher median concentrations of IL-5 (0.11 ng/mgtotal protein vs. 0.08 ng/mgtotal protein), IL-9 (2.7 ng/mgtotal protein vs. 2.1 ng/mgtotal protein), IL-13 (2.1 ng/mgtotal protein vs. 0.9 ng/mgtotal protein), IL-17 (2.9 ng/mgtotal protein vs. 1.1 ng/mgtotal protein), EOTAXIN (4.1 ng/mgtotal protein vs. 1.1 ng/mgtotal protein), GM-CSF (4.3 ng/mgtotal protein vs. 3.3 ng/mgtotal protein), and MIP-1α (3.5 ng/mgtotal protein vs. 1.9 ng/mgtotal protein) compared to HR-HPV negative women. A shift in the correlation of T-cell and pro-inflammatory cytokines (IFN-γ, IL-5, IL-9, IL-10, IL-12, IL-13, IL-15, and TNF-α) from IL-2 to EOTAXIN was observed between HR-HPV negative and positive women. CONCLUSIONS: Higher local concentrations of anti-inflammatory and allergy associated markers, with a shift in T-cell associated cytokine correlation from IL-2 to EOTAXIN, are associated with HPV infection among older women.


Subject(s)
Biomarkers/metabolism , Cervix Uteri/immunology , Cervix Uteri/virology , Papillomaviridae/physiology , Papillomavirus Infections/immunology , Papillomavirus Infections/virology , Perimenopause/immunology , Cytokines/metabolism , Female , Gene Regulatory Networks , Humans , Hypersensitivity/complications , Hypersensitivity/immunology , Hypersensitivity/pathology , Inflammation/complications , Inflammation/immunology , Inflammation/pathology , Limit of Detection , Middle Aged , T-Lymphocytes/immunology
5.
J Infect Dis ; 203(8): 1182-91, 2011 Apr 15.
Article in English | MEDLINE | ID: mdl-21451006

ABSTRACT

BACKGROUND: Individuals who acquire human immunodeficiency virus (HIV) may experience an immediate disruption of genital tract immunity, altering the ability to mount a local and effective immune response. This study examined the impact of early HIV infection on new detection of human papillomavirus (HPV). METHODS: One hundred fifty-five Zimbabwean women with observation periods before and after HIV acquisition and 486 HIV-uninfected women were selected from a cohort study evaluating hormonal contraceptive use and risk of HIV acquisition. Study visits occurred at 3-month intervals. Cervical swab samples available from up to 6 months before, at, and up to 6 months after the visit when HIV was first detected were typed for 37 HPV genotypes or subtypes. RESULTS: We observed ∼5-fold higher odds of multiple (≥2) new HPV detections only after HIV acquisition, relative to HIV-negative women after adjusting for sexual behavior and concurrent genital tract infections. We also observed ∼2.5-fold higher odds of single new HPV detections at visits before and after HIV acquisition, relative to HIV-uninfected women in multivariable models. CONCLUSIONS: These findings suggest that HIV infection has an immediate impact on genital tract immunity, as evidenced by the high risk of multiple new HPV detections immediately after HIV acquisition.


Subject(s)
Alphapapillomavirus/isolation & purification , HIV Infections/complications , HIV Infections/epidemiology , Papillomavirus Infections/complications , Papillomavirus Infections/epidemiology , Adolescent , Adult , CD4-Positive T-Lymphocytes , Cohort Studies , Female , Humans , Young Adult , Zimbabwe/epidemiology
6.
J Clin Microbiol ; 48(12): 4646-8, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20926711

ABSTRACT

In a feasibility study using a prototype, lateral-flow test for human papillomavirus type 16, 18, and/or 45 (HPV16/18/45) E6 oncoproteins, 51 of 75 (68%; 95% confidence interval [95% CI] of 56 to 78%) of HPV16/18/45 DNA-positive specimens from women with a diagnosis of CIN3+ (cervical intraepithelial neoplasia grade 3+ or cervical cancer) tested positive for HPV16/18/45 E6 oncoprotein. None of 16 (95% CI of 0 to 37%) HPV16/18/45 DNA-positive cervical specimens from women with a negative or CIN1 diagnosis tested positive for HPV16/18/45 E6 oncoprotein.


Subject(s)
Oncogene Proteins, Viral/analysis , Papillomavirus Infections/complications , Papillomavirus Infections/diagnosis , Uterine Cervical Neoplasms/diagnosis , Uterine Cervical Neoplasms/virology , Virology/methods , Feasibility Studies , Female , Humans , Immunoassay/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...